Dr. Siddiqui is an Assistant Professor in Genitourinary Medical Oncology at the University of Texas MD Anderson. He is a clinical and translational investigator with a focus on:1) biomarker-rich trials of novel immunotherapy strategies in prostate cancer, with a special emphasis on T cell engagers; and 2) improving outcomes in immune-mediated toxicities through identification of mechanistic biomarkers for early detection and rational intervention. He serves as a principal investigator on multiple clinical trials of T cell engagers in prostate cancer, including leading multicenter sponsored trials and investigator-initiated studies. He is a member of the MD Anderson IOTOX Leaders’ Group, meeting a critical need as immunotherapy combinations with higher rates of toxicities are growing rapidly. He has a special interest in immune-mediated myocarditis and myositis, which carry a high mortality rate. His recent work identified a novel population of IL-1-
expressing macrophages in human heart tissue from patients with immune-mediated myocarditis that represents a potential therapeutic target for which a rational clinical trial is under development. The long-term goals of this work is to maximize efficacy and minimize toxicities of these immunotherapy strategies in patients.